雷贝拉唑、铝碳酸镁和莫沙必利联合治疗胆囊切除术后胆汁反流性胃炎的临床观察

目的：观察雷贝拉唑、铝碳酸镁和莫沙必利联合治疗胆囊切除术后胆汁反流性胃炎的临床疗效。方法101例胆汁反流性胃炎患者分为A （36例）、B （34例）、C （31例）3组，其中A组采用雷贝拉唑、铝碳酸镁和莫沙必利联合治疗，B组采用雷贝拉唑和莫沙必利联合治疗，C组采用铝碳酸镁和莫沙必利治疗。疗程均为4周。根据症状严重程度及发作频率的评分和复查胃镜所见胃黏膜炎症的转归及胆汁反流程度的胃镜分级作为临床观察和疗效评定的指标。结果治疗4周后，A组临床症状改善总有效率为94.4％，B组为85.3％，C组为67.7％，A组临床症状改善总有效率明显高于B组和C 组（P＜0.05）；A 组胆汁反流入胃现象明显少于 B 组和 C 组（97.2 vs 88.2％ vs 71.0％）。结论雷贝拉唑、铝碳酸镁和莫沙必利联合治疗胆囊切除术后的胆汁反流性胃炎，既能有效地改善症状，又能有效的减轻胆汁反流入胃内。

Clinical effects of combination of Rebeprazole,Hydrotalcite and Mosapride on patients with bile reflux gastritis after cholecystectomy

Objective To study the effects of combination of rebeprazole,hydrotalcite and mosapride on patients with bile reflux gastritis after cholecystectomy. Methods One hundred and one patients diagnosed with bile reflux gastritis by endoscopy were randomly divided into Group A （36 patients）,Group B （34 pa-tients）and Group C （31 patients）,and treated with rebeprazole plus hydrotalcite plus mosapride,rebeprazole plus mosapride,hydrotalcite plus mosapride,respectively. The clinical outcome was analyzed after 4 weeks of treatment. Results After 4 weeks of treatment,the total improvement rate in group A （94.4%）was higher than that in Group B （85.3%） and C （67.7%） （P〈0.05 ）. The incidence of bile backflow into stomach was significantly more reduced in group A （97.2%）than that in group B （88.2%）and C （7 1.0%）. Con-clusions Rebeprazole combined with hydrotalcite and mosapride is effective in the treatment of patients with bile reflux gastritis after-cholecystectomy.